Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

, CELG

Celgene

$118.51

-3.62 (-2.96%)

18:01
11/30/16
11/30
18:01
11/30/16
18:01

bluebird bio jumps after early data on CAR-T myeloma treatment

As part of an announcement of presentations at an upcoming medical symposium, bluebird bio (BLUE) reported interim data from the Phase 1 study of bb2121, its CAR-T treatment candidate for relapsed refractory multiple myeloma. As of the November 18 cut-off, 11 patients had been enrolled and dosed in four cohorts. All 11 dosed patients were evaluable for safety, and the first nine patients have undergone their first multiple myeloma tumor restaging and were evaluable for efficacy. One hundred percent of patients in the second and third cohorts achieved an objective response. Two patients are MRD-negative, and the overall response rate was 78%. Two patients achieved stringent complete responses, with six and four months follow-up. All patients in cohorts two and three with bone marrow involvement at baseline had no detectable multiple myeloma cells in their bone marrow on day 14 or beyond. Among all dosed patients, no dose-limiting toxicities were observed to date, and no Grade 3 or 4 cytokine release syndrome or neurotoxicity was observed. Commenting on the news, Chief Medical Officer David Davidson said the company is "pleased" with the early data, adding that "in light of these positive data, and thanks to the multiple participating clinical sites and centralized manufacturing infrastructure we and our partner Celgene (CELG) have built for this program, we anticipate efficiently completing the dose escalation stage of the trial and initiating the expansion cohort." PRICE ACTION: Shares of bluebird bio are up 14.3% to $69.00 in after-hours trading, while Celgene is up 0.92%.

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

CELG

Celgene

$118.51

-3.62 (-2.96%)

  • 30

    Nov

  • 30

    Nov

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

BLUE bluebird bio
$60.35

-4.05 (-6.29%)

11/23/16
JANY
11/23/16
NO CHANGE
JANY
Weakness in bluebird bio unwarranted after Juno trial halt, says Janney Capital
11/23/16
11/23/16
NO CHANGE

Buy
bluebird bio weakness unwarranted after Juno trial halt, says Janney Capital
As previously reported, Janney Capital analyst Debjit Chattopadhyay said the weakness in bluebird bio (BLUE) is unwarranted on the heels of Juno's (JUNO) second clinical hold for JCAR015. Chattopadhyay notes several key differences between JCAR015 and bluebird's bb2121, including their targets, diseases, vectors, preconditioning regimens and others. He remains a buyer of bluebird ahead of a "potentially watershed ASH for its lentiglobin platform" and keeps a Buy rating on the stock.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
11/29/16
PIPR
11/29/16
NO CHANGE
PIPR
Piper sees bluebird regaining 'mojo and momentum'
After hosting management for an investor dinner, Piper Jaffray analyst Joshua Schimmer sees bluebird bio regaining its "mojo and momentum." The analyst expects a "steady stream of positive updates and derisking" starting with BCMA CAR-T data update this week and extending into optimizing LentiGlobin's profile for sickle cell and betathal in 2017. Schimmer has an Overweight rating on bluebird shares with a $95 price target. The biotechnology company closed yesterday down 5% to $60.65.
CELG Celgene
$118.51

-3.62 (-2.96%)

11/09/16
STPT
11/09/16
DOWNGRADE
STPT
Hold
Celgene downgraded to Hold from Buy at Standpoint Research
11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
11/28/16
OPCO
11/28/16
INITIATION
Target $141
OPCO
Outperform
Celgene initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leah Cann initiated Celgene with an Outperform rating and $141 price target, estimating that revenue will grow at a compound annual growth rate of 19% per year for the next five years and that its GAAP EPS can grow by a 31% CAGR over the same span.

TODAY'S FREE FLY STORIES

BBRY

BlackBerry

$9.85

0.71 (7.77%)

13:45
09/21/17
09/21
13:45
09/21/17
13:45
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

13:45
09/21/17
09/21
13:45
09/21/17
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

ICPT

Intercept

$98.12

1.92 (2.00%)

13:41
09/21/17
09/21
13:41
09/21/17
13:41
Hot Stocks
Breaking Hot Stocks news story on Intercept »

Intercept selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
09/21/17
09/21
13:40
09/21/17
13:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

HDSN

Hudson Technologies

$9.26

-0.03 (-0.32%)

13:39
09/21/17
09/21
13:39
09/21/17
13:39
Technical Analysis
Technical View: Hudson Technologies down on cautious Seeking Alpha mention »

The shares have taken a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

HDSN

Hudson Technologies

$9.26

-0.03 (-0.32%)

13:34
09/21/17
09/21
13:34
09/21/17
13:34
Periodicals
Hudson Technologies mentioned cautiously by Seeking Alpha contributor 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

OUT

Outfront Media

$21.19

-0.2 (-0.94%)

, LAMR

Lamar Advertising

$64.42

0.45 (0.70%)

13:30
09/21/17
09/21
13:30
09/21/17
13:30
Hot Stocks
Before the Move: Watch Outfront Media ahead of NYC-MTA contract decision »

A decision regarding the…

OUT

Outfront Media

$21.19

-0.2 (-0.94%)

LAMR

Lamar Advertising

$64.42

0.45 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ILG

ILG

$25.87

0.56 (2.21%)

, VAC

Marriott Vacations

$119.30

5.31 (4.66%)

13:24
09/21/17
09/21
13:24
09/21/17
13:24
Periodicals
FrontFour plans ILG proxy fight if deal not struck this year, Bloomberg says »

FrontFour Capital, a…

ILG

ILG

$25.87

0.56 (2.21%)

VAC

Marriott Vacations

$119.30

5.31 (4.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

DDAIF

Daimler AG

$79.46

-0.16 (-0.20%)

, TSLA

Tesla

$373.91

-1.19 (-0.32%)

13:21
09/21/17
09/21
13:21
09/21/17
13:21
Hot Stocks
Mercedes-Benz to start production of electric passenger cars in U.S. »

Mercedes-Benz will set up…

DDAIF

Daimler AG

$79.46

-0.16 (-0.20%)

TSLA

Tesla

$373.91

-1.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MSFT

Microsoft

$74.94

-0.5 (-0.66%)

13:20
09/21/17
09/21
13:20
09/21/17
13:20
Options
Notable call write in Microsoft »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 22

    Oct

$NSD

NASDAQ Market Internals

13:17
09/21/17
09/21
13:17
09/21/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
09/21/17
09/21
13:16
09/21/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
09/21/17
09/21
13:15
09/21/17
13:15
General news
Treasury's $11 B 10-year TIPS reopening was poorly received »

Treasury's $11 B…

XOP

SPDR Oil Exploration and Production Fund

$32.88

0.02 (0.06%)

13:10
09/21/17
09/21
13:10
09/21/17
13:10
Options
Hefty put spread in SPDR Oil and Gas Exploration ETF »

Hefty put spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIP

TripAdvisor

$43.92

0.32 (0.73%)

13:05
09/21/17
09/21
13:05
09/21/17
13:05
Options
TripAdvisor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:04
09/21/17
09/21
13:04
09/21/17
13:04
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

13:04
09/21/17
09/21
13:04
09/21/17
13:04
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

ZGNX

Zogenix

$13.60

-0.95 (-6.53%)

12:55
09/21/17
09/21
12:55
09/21/17
12:55
Options
Zogenix put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$21.55

0.6 (2.86%)

12:51
09/21/17
09/21
12:51
09/21/17
12:51
Periodicals
Impax merger with Amneal could come next month, WSJ reports »

Impax and Amneal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CAR

Avis Budget

$37.92

1.28 (3.49%)

12:40
09/21/17
09/21
12:40
09/21/17
12:40
Options
Avis attracts a put buyer »

Avis attracts a put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

12:40
09/21/17
09/21
12:40
09/21/17
12:40
General news
Treasury 10-year TIPS preview »

Treasury 10-year TIPS…

GIS

General Mills

$51.80

-0.3658 (-0.70%)

12:30
09/21/17
09/21
12:30
09/21/17
12:30
Options
Position adjustment in General Mills after earnings »

Position adjustment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$5.60

-0.08 (-1.41%)

12:29
09/21/17
09/21
12:29
09/21/17
12:29
Upgrade
Ericsson rating change  »

Ericsson upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$6.09

-0.095 (-1.54%)

12:29
09/21/17
09/21
12:29
09/21/17
12:29
Downgrade
Nokia rating change  »

Nokia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$947.54

10.68 (1.14%)

, TWTR

Twitter

$17.59

-0.035 (-0.20%)

12:26
09/21/17
09/21
12:26
09/21/17
12:26
Periodicals
Google, Twitter could be involved in investigation on Russia, Recode reports »

The congressional…

GOOGL

Alphabet Class A

$947.54

10.68 (1.14%)

TWTR

Twitter

$17.59

-0.035 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.